United Therapeutics Corporation

UTHR | NASDAQ

Price Alert Chart Builder DCF Calculator

$493.10

-$1.53 (-0.31%)

At close: Sep 21, 2026, 4:00 PM ET

$492.77

-$0.33 (-0.07%)

Pre-market: Sep 22, 2026, 5:41 AM ET

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

Market Data

Market Cap $21B

Enterprise Value $18.27B

Beta 0.56

Average Volume 499.03K

Shares Outstanding (Diluted) 45.8M

Shares Change YoY -5.18%

Institutional Ownership 95.41%

Exchange NASDAQ

ISIN US91307C1027

Price Performance

Price Change 1M -3.9%

Price Change 3M -9.4%

Price Change 6M -8.9%

Price Change YTD -0.7%

Price Change 1Y 18.9%

Price Change 3Y 121.4%

Price Change 5Y 152.7%

1M CAGR (ann.) -7.2%

1Y CAGR (ann.) 22.5%

5Y CAGR (ann.) 18.7%

All-Time CAGR 15.1%

Valuation

PE Ratio 17.67

Forward PE 15.27

PEG Ratio 1.80

Forward PEG 1.52

PS Ratio 6.64

Forward PS 6.10

PB Ratio 3.27

P/FCF Ratio 14.38

P/Adj. FCF Ratio 16.10

P/OCF Ratio 12.46

EV/Sales 5.79

EV/EBIT 11.53

EV/EBITDA 11.06

EV/FCF 12.55

Earnings Yield 5.7%

FCF Yield 7.0%

Adj. FCF Yield 6.2%

Financial Health

Net Cash $2.66B

Total Debt $0

Cash & Short-Term Investments $2.66B

Total Assets $7.22B

Current Ratio 5.73

Quick Ratio 5.41

Debt / Equity Ratio 0.00

Debt / EBITDA 0.00

Debt / FCF 0.00

OCF / Debt N/A

Interest Coverage 116.95

Altman Z-Score 18.78

Piotroski F-Score 6

Margins & Profitability

Gross Profit Margin 86.1%

Operating Profit Margin 44.5%

EBITDA Margin 52.4%

Net Profit Margin 41.6%

FCF Margin 46.1%

Adj. FCF Margin 41.2%

SBC / Revenue 4.9%

SBC Impact (per share) -10.7%

Returns

Return on Assets 18.2%

Return on Equity 20.2%

Return on Invested Capital 17.7%

Return on Capital Employed 21.2%

Return on Tangible Assets 18.4%

Historical Growth (CAGR)

Revenue CAGR 3Y 14.3%

Revenue CAGR 5Y 14.7%

Revenue CAGR 10Y 7.2%

EPS CAGR 3Y 16.4%

EPS CAGR 5Y 22.1%

EPS CAGR 10Y 3.1%

FCF CAGR 3Y 29.3%

FCF CAGR 5Y 21.1%

FCF CAGR 10Y 13.2%

Analyst Forecasts

Analyst Rating Buy

Analyst Count 30

EPS Growth Next 3Y 11.7%

Revenue Growth Next 3Y 14.5%

Earnings Date Nov 3, 2026

EPS Estimate (next Q) $6.44

EPS Growth Est (next Q) -10.1%

Revenue Est (next Q) $789.51M

Revenue Growth Est (next Q) -1.3%

Fair Value Estimates

Graham Number $307.16

Graham Upside -37.7%

Lynch Fair Value $616.53

Lynch Upside 25.0%

Price Target $650

Price Target Upside 31.8%

Cash Flow

Operating Cash Flow $2.15B

Free Cash Flow $1.46B

Adj. Free Cash Flow $1.3B

FCF Per Share $25.66

OCF Per Share $39.56

OCF/S Ratio 53.4%

Income Statement

Revenue $3.15B

Gross Profit $2.72B

Operating Income $1.4B

EBITDA $1.65B

Net Income $1.31B

EPS (Diluted) $27.91

Revenue / Employee $2.25M

Profit / Employee $936.36K

Employees 1,400